Citadel Advisors LLC Raises Holdings in Nautilus Biotechnology, Inc. (NASDAQ:NAUT)

Citadel Advisors LLC grew its position in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) by 171.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 220,220 shares of the company’s stock after buying an additional 139,081 shares during the quarter. Citadel Advisors LLC owned 0.18% of Nautilus Biotechnology worth $370,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the company. Virtu Financial LLC purchased a new stake in Nautilus Biotechnology in the fourth quarter worth about $28,000. SG Americas Securities LLC lifted its position in shares of Nautilus Biotechnology by 56.3% in the 4th quarter. SG Americas Securities LLC now owns 27,483 shares of the company’s stock worth $46,000 after purchasing an additional 9,904 shares during the period. Palumbo Wealth Management LLC lifted its position in shares of Nautilus Biotechnology by 45.4% in the 4th quarter. Palumbo Wealth Management LLC now owns 28,475 shares of the company’s stock worth $48,000 after purchasing an additional 8,888 shares during the period. Bank of America Corp DE lifted its position in shares of Nautilus Biotechnology by 37.1% in the 4th quarter. Bank of America Corp DE now owns 49,419 shares of the company’s stock worth $83,000 after purchasing an additional 13,363 shares during the period. Finally, Hsbc Holdings PLC lifted its position in shares of Nautilus Biotechnology by 182.5% in the 4th quarter. Hsbc Holdings PLC now owns 55,184 shares of the company’s stock worth $92,000 after purchasing an additional 35,650 shares during the period. 50.71% of the stock is currently owned by hedge funds and other institutional investors.

Nautilus Biotechnology Price Performance

Shares of NASDAQ NAUT opened at $0.77 on Wednesday. The stock has a market capitalization of $96.86 million, a P/E ratio of -1.37 and a beta of 1.41. The business has a fifty day moving average price of $0.76 and a 200 day moving average price of $1.38. Nautilus Biotechnology, Inc. has a 1-year low of $0.66 and a 1-year high of $3.09.

Nautilus Biotechnology (NASDAQ:NAUT) last released its quarterly earnings results on Tuesday, April 29th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.01. As a group, equities research analysts anticipate that Nautilus Biotechnology, Inc. will post -0.57 earnings per share for the current fiscal year.

Insider Activity at Nautilus Biotechnology

In other Nautilus Biotechnology news, CEO Sujal M. Patel purchased 53,300 shares of the firm’s stock in a transaction on Wednesday, March 19th. The stock was bought at an average cost of $0.99 per share, for a total transaction of $52,767.00. Following the completion of the purchase, the chief executive officer now owns 10,117,788 shares in the company, valued at $10,016,610.12. This represents a 0.53% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders bought 81,800 shares of company stock valued at $74,172 over the last 90 days. Insiders own 41.10% of the company’s stock.

Analyst Ratings Changes

Separately, Guggenheim set a $2.50 target price on Nautilus Biotechnology in a report on Friday, February 28th.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.